Active	Status	Sponsor type	Region	Phase	Filter
8 Active 2 Inactive 10 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Chen, Kevin W
MGC018-SCLC, NCT06227546: MGC018 in Patients With Relapsed or Refractory Extensive-Stage Small-Cell Lung Cancer	Recruiting	2	17	US	MGC018	Georgetown University, MacroGenics	Extensive-stage Small-cell Lung Cancer	05/25	05/26
NCT04499053: Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer	Recruiting	2	18	US	Durvalumab, Tremelimumab	Georgetown University, AstraZeneca	Carcinoma, Non-Small Cell Lung	02/27	12/27
MRD, NCT05210283: CORRECT Study of Minimal Residual Disease Detection in Colorectal Cancer	Recruiting	N/A	750	Canada, US	MRD	Exact Sciences Corporation, NSABP Foundation Inc	Colorectal Cancer	02/28	02/28
Avergas, Amy
NCT06246110: A Phase 2 Study of EIK1001 in Combo with Pembrolizumab and Chemotherapy in Patients with Stage 4 NSCLC	Recruiting	2	70	US	EIK1001, Pembrolizumab, Paclitaxel, Pemetrexed, Carboplatin	Eikon Therapeutics	NSCLC	12/26	12/27
NCT04499053: Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer	Recruiting	2	18	US	Durvalumab, Tremelimumab	Georgetown University, AstraZeneca	Carcinoma, Non-Small Cell Lung	02/27	12/27